Starting September 2025, our teams will be offering Vikaly to European professionals and pet owners. This disruptive innovation, at the crossroads of our expertise in veterinary medicine and animal nutrition, foreshadows the emergence of a new therapeutic model, better adapted to daily constraints, aligned with contemporary veterinary practices, the expectations of pet owners, and animal welfare. Designed, developed, and manufactured in France, Vikaly demonstrates the commitment of our teams and our ability to open new paths in the management of companion animal health.

Find details of the 2025 half-year results

Our team, responsible for drug registration and maintaining and defending Marketing Authorizations (MAs), is ready to reveal what they do.